15.89

0.06% -0.010

After Hours: 15.88 -0.010 -0.06%

enGene Holdings Inc (ENGN)

Overview News Price History Discussions Forecast

enGene Holdings Inc stock is currently priced at $15.89, with a 24-hour trading volume of 18,432. It has seen a -0.06% decreased in the last 24 hours and a -5.92% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $15.97 pivot point. If it approaches the $15.43 support level, significant changes may occur.

Previous Close:

$15.90

Open:

$15.46

24h Volume:

18,432

Market Cap:

$700.76M

Revenue:

Net Income/Loss:

$-103.21M

P/E Ratio:

EPS:

Net Cash Flow:

$-26.70M

1W Performance:

+7.73%

1M Performance:

-5.92%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1D Range:

$15.44

$16.25

52W Range:

$6.69

$18.40

enGene Holdings Inc Stock (ENGN) Company Profile

Name

enGene Holdings Inc

Sector

Healthcare (1189)

Industry

Biotechnology (685)

Phone

514 332 4888

Address

7171 Rue Frederick Banting, Saint-Laurent

Employee

Twitter

Next Earnings Date

Latest SEC Filings

ENGN's Discussions on Twitter

enGene Holdings Inc Stock (ENGN) Latest News

Why AppLovin Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket

Benzinga

Cisco Issues Weak Outlook, Joins Fastly, Herbalife And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Benzinga

Dow Edges Higher; QuidelOrtho Shares Plummet

Benzinga

Why Sony Shares Are Trading Lower By Around 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Crude Oil Moves Lower; Louisiana-Pacific Posts Upbeat Earnings

Benzinga

Why Methode Electronics Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

enGene Holdings Inc Stock (ENGN) Financials Data

enGene Holdings Inc (ENGN) Net Income 2024

ENGN net income (TTM) was -$103.21 million for the quarter ending January 31, 2024, a -270.53% decrease year-over-year.

enGene Holdings Inc (ENGN) Cash Flow 2024

ENGN recorded a free cash flow (TTM) of -$26.70 million for the quarter ending January 31, 2024.

enGene Holdings Inc (ENGN) Earnings per Share 2024

ENGN earnings per share (TTM) was -$4.6001 for the quarter ending January 31, 2024, a -228.77% decline year-over-year.

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.